The burden of psoriasis is not determined by disease severity only.
about
Topical treatments for scalp psoriasisImpact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].Nail Psoriasis: A Review of Treatment OptionsRecommendations for a patient-centered approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group.Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study.XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasis.Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial.Current severe psoriasis and the rule of tens.A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1Emerging drugs for psoriasis.Optimism as a predictor of health-related quality of life in psoriatics.Maximizing patient adherence for optimal outcomes in psoriasis.Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement.Non-adherence and measures to improve adherence in the topical treatment of psoriasis.Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice.Correlation between Dermatology Life Quality Index (DLQI) scores and Work Limitations Questionnaire (WLQ) allows the calculation of percent work productivity loss in patients with psoriasis.New insight into the pathogenesis of nail psoriasis and overview of treatment strategies.Assessment of severity of hand eczema: discrepancies between patient- and physician-rated scores.Pasi and pqol-12 score in psoriasis: is there any correlation?Determinants of social anxiety and social avoidance in psoriasis outpatients.Clinical and psychological characteristics of patients with psoriasis reporting various frequencies of pruritus.Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.A prospective cross-sectional study of anxiety and depression in patients with psoriasis in Singapore.A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL).Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA.Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.SF-36 healty survey on psoriasis quality-of-life: a study of 414 Taiwanese patients.Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis.Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis.Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases.The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey.The burden of psoriasis in Canada: insights from the pSoriasis Knowledge IN Canada (SKIN) survey.Measuring quality of life of patients with different clinical types of psoriasis using the SF-36.[Development of the evidence-based guidelines for psoriasis--a project of the German Dermatological Society (DDG)].Health-related quality of life in patients with psoriasis.Turkish version of Skindex-29.
P2860
Q24186104-614CD214-5C4A-42BB-A049-36767F5FE9B9Q25256974-D0E7BD06-7102-4088-94C3-4F0CDD1EEE6DQ26753038-23D85126-59AD-4BA3-9688-A52C0395C417Q34452903-B3C78CD1-847D-4C44-9125-96531FA1B391Q34497024-B1A24846-7C3F-4D16-926B-3EB1CC20DC0AQ34585886-8D805F10-796F-4279-B43A-A8F6CE2D82D2Q34996214-01B86DDC-A1DA-42E8-BB55-586FA593A226Q36124195-4094AA05-B264-418F-A6AF-35D61A7177C1Q36434758-172C4638-3F4D-46B7-9BCD-10BA68A6380CQ36634244-BE8D556A-6992-4DAD-98DA-1572CA12B239Q37327130-396FD7CE-BF15-482C-876E-B14BFC311A5DQ37867174-BF9B7670-42DD-48A8-B4FC-43DA37794B93Q37961072-FB3CA6FB-BC19-4E43-ACFD-8C178931CCC4Q38200706-B73C53B7-6623-406A-9E9C-E48CCB2D5F90Q38632525-E0279C7F-986E-4E7B-ACEE-6B5D36196CCFQ40390231-561CC7FE-90BD-4286-951A-4504A78CB812Q40977555-E248FC5B-4837-4FDA-9C61-D614F3D745D1Q41633453-E559BC2E-A74B-484F-BC73-97726495F735Q42603551-682A4389-FD4E-4186-B54D-446C74752BCCQ42792535-7B50FA89-8305-48F0-863A-AB153639C573Q44290424-E66F02AF-E834-4B7D-A4BE-D06394DCEE76Q44612259-D1A8F0BB-4B57-4DEC-AF00-EAF7C8D4B7A9Q44773623-364708FA-853D-41C7-9CE8-D5CA3A3F38CDQ47445839-57C3D053-61B0-4E53-A5E9-B271E436CCB0Q47776771-F39E40B2-0ABE-4C99-B027-4866BDC5BB4EQ47777458-867A83BD-CCFD-425A-A5D4-FFCD8DA903EBQ47892380-9B1F93A5-B662-4460-940B-9405697E8B3CQ48053421-C60BE39C-77D2-4D6C-88D4-79B3BDF59610Q48313359-9D948C2D-EF83-4678-8C9E-B0574FB681F7Q48566723-A4F14E72-6C69-45E2-996A-211AE64053EDQ48580332-069301F7-090E-4F5D-B94A-EF640B034AA2Q48952489-03E0C7E1-BFA2-490C-9671-9DD93D2E7DFCQ49024262-BEAC50E9-026C-4CAA-9CFD-19332113D1B8Q51918693-9FD81154-CE2B-421A-9BF6-B08BB4825CF7Q52936624-8ABC4DEA-AC77-443A-8603-99F8E364C9FEQ53051911-0F2ACA7A-75FC-4DDF-B76F-1DC96D277D06Q53196141-E43C0F88-D021-468F-B00B-380EDF82DC5B
P2860
The burden of psoriasis is not determined by disease severity only.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The burden of psoriasis is not determined by disease severity only.
@en
The burden of psoriasis is not determined by disease severity only.
@nl
type
label
The burden of psoriasis is not determined by disease severity only.
@en
The burden of psoriasis is not determined by disease severity only.
@nl
prefLabel
The burden of psoriasis is not determined by disease severity only.
@en
The burden of psoriasis is not determined by disease severity only.
@nl
P2093
P1476
The burden of psoriasis is not determined by disease severity only.
@en
P2093
Corianne A de Borgie
Menno A de Rie
Patrick M Bossuyt
Phyllis I Spuls
Vera M Heydendael
P304
P356
10.1111/J.1087-0024.2004.09115.X
P577
2004-03-01T00:00:00Z
P6179
1050408450